On October 29, 2024, Verde announced significant assay results from over 1,500 meters of exploration, identifying rare earth ...

Immatics (IMTX) has released an update. Immatics is showcasing promising advancements in its TCR-T therapy candidates targeting PRAME, with significant responses in metastatic melanoma patients and ...

Jonathan Chang has given his Buy rating due to a combination of factors, including the promising results from Immatics’ ongoing clinical trials. The updated Phase I data for IMA203 and IMA203CD8, ...

Avidity Biosciences, Inc. (RNA) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock To get a sense of who is truly in control of Immatics N.V. (NASDAQ:IMTX), it is ...

Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock To get a sense of who is truly in control of Immatics N.V. (NASDAQ:IMTX), it is ...

Immatics (NASDAQ:IMTX – Get Free Report) was the recipient of a significant drop in short interest during the month of September.As of September 30th, there was short interest totalling ...

The stock of Immatics N.V (IMTX) has seen a -14.00% decrease in the past week, with a -25.04% drop in the past month, and a -25.64% decrease in the past quarter. The volatility ratio for the week is 6 ...

NEW YORK – A group of Australian universities and cancer institutes announced on Monday they have launched the Victorian Paediatric Cancer Consortium (VPCC) to help advance treatments for pediatric ...